Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
$1.28
-4.1%
$1.28
$0.85
$4.40
$40.54M0.2931,765 shs7,471 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.89
-6.4%
$0.96
$0.40
$5.12
$13.44M1.641.46 million shs355,183 shs
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$35.25
-0.6%
$37.67
$1.72
$54.30
$215.55M1.11359,453 shs12,005 shs
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
$2.43
+0.8%
$2.32
$1.90
$4.21
$69.56M0.67170,655 shs118,384 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
+0.39%-1.51%-10.49%+36.90%-34.36%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-6.41%-9.17%-16.04%-29.37%-81.95%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-0.56%-4.47%-17.47%+12.66%+1,021.00%
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
+0.83%-7.60%+9.46%-6.90%-40.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.1008 of 5 stars
3.52.00.00.02.70.01.3
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.9492 of 5 stars
3.45.00.00.03.02.50.0
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
1.9156 of 5 stars
0.05.00.00.02.71.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
0.00
N/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$6.00574.16% Upside
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.75
Moderate Buy$55.3356.97% Upside
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest MBRX, MNPR, AKTX, and VTGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/1/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
3/25/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$4.00
3/24/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
3/19/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$76.00
3/3/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A($0.03) per shareN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$11.70 per shareN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$1.88 per shareN/A
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
$698K100.48N/AN/A$2.81 per share0.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
-$10.01MN/A0.00N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$29.77MN/A0.00N/AN/AN/A-157.44%-97.16%8/12/2025 (Estimated)
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
-$29.36M-$1.48N/AN/AN/A-6,777.08%-48.12%-43.80%6/10/2025 (Estimated)

Latest MBRX, MNPR, AKTX, and VTGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/10/2025Q4 2025
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
-$0.53N/AN/AN/A$0.18 millionN/A
5/13/2025Q1 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.71-$0.69+$0.02-$0.69N/AN/A
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
3/31/2025Q4 2024
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.36-$2.23-$1.87-$2.23N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/A
0.29
0.29
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
2.08
2.08
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
5.41
5.41
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
N/A
9.35
9.35

Institutional Ownership

CompanyInstitutional Ownership
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
5.06%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
78.39%

Insider Ownership

CompanyInsider Ownership
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
38.90%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1.90%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
20.50%
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
1.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
932.18 million16.25 millionNot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2014.13 million3.86 millionNot Optionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million3.97 millionNot Optionable
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
4028.86 million28.49 millionOptionable

Recent News About These Companies

VistaGen’s Earnings Call: Progress and Challenges
Vistagen reports Q3 EPS (46c) vs (22c) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akari Therapeutics stock logo

Akari Therapeutics NASDAQ:AKTX

$1.28 -0.06 (-4.12%)
Closing price 05/27/2025 03:56 PM Eastern
Extended Trading
$1.27 -0.01 (-0.78%)
As of 05/27/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.89 -0.06 (-6.41%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$0.90 +0.02 (+1.69%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$35.25 -0.20 (-0.56%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$36.80 +1.55 (+4.40%)
As of 05/27/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Vistagen Therapeutics stock logo

Vistagen Therapeutics NASDAQ:VTGN

$2.43 +0.02 (+0.83%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.44 +0.00 (+0.21%)
As of 05:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.